Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to -$30.2 million.

  • Macrogenics' Cash from Operations fell 15017.45% to -$30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.5 million, marking a year-over-year decrease of 18010.28%. This contributed to the annual value of -$68.4 million for FY2024, which is 1257.21% up from last year.
  • As of Q3 2025, Macrogenics' Cash from Operations stood at -$30.2 million, which was down 15017.45% from -$47.0 million recorded in Q2 2025.
  • Over the past 5 years, Macrogenics' Cash from Operations peaked at $60.2 million during Q3 2024, and registered a low of -$57.7 million during Q1 2022.
  • Its 5-year average for Cash from Operations is -$26.4 million, with a median of -$35.2 million in 2023.
  • Over the last 5 years, Macrogenics' Cash from Operations had its largest YoY gain of 27069.17% in 2024, and its largest YoY loss of 202948.78% in 2024.
  • Quarter analysis of 5 years shows Macrogenics' Cash from Operations stood at -$54.3 million in 2021, then surged by 153.99% to $29.3 million in 2022, then crashed by 195.62% to -$28.0 million in 2023, then crashed by 36.99% to -$38.4 million in 2024, then rose by 21.4% to -$30.2 million in 2025.
  • Its Cash from Operations stands at -$30.2 million for Q3 2025, versus -$47.0 million for Q2 2025 and -$46.9 million for Q1 2025.